A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

NCT06614192 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Telisotuzumab Adizutecan
DRUG: Trifluridine/Tipiracil
DRUG: Bevacizumab

Sponsor

AbbVie